[1] Liaw YF, Chu CM. Hepatitis B virus infection. Lancet, 2009; 373, 582−92. doi:  10.1016/S0140-6736(09)60207-5
[2] Yano Y, Azuma T, Hayashi Y. Variations and mutations in the hepatitis B virus genome and their associations with clinical characteristics. World J Hepatol, 2015; 7, 583−92. doi:  10.4254/wjh.v7.i3.583
[3] McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis 2005; 25, 3−8.
[4] Amponsah-Dacosta E. Hepatitis B virus infection and hepatocellular carcinoma in sub-Saharan Africa: Implications for elimination of viral hepatitis by 2030? World J Gastroenterol, 2021; 27, 6025-38.
[5] Ong HT, Duraisamy G, Peng NK, et al. Genotyping of hepatitis B virus in Malaysia based on the nucleotide sequence of preS and S genes. Microbes Infect, 2005; 7, 494−500. doi:  10.1016/j.micinf.2004.12.016
[6] Ganem D, Prince AM. Hepatitis B virus infection—natural history and clinical consequences. N Engl J Med, 2004; 350, 1118−29. doi:  10.1056/NEJMra031087
[7] Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. Nat Med, 2013; 19, 1597−608. doi:  10.1038/nm.3409
[8] Mahdavi M, Ebtekar M, Khorshid HRK, et al. ELISPOT analysis of a new CTL based DNA vaccine for HIV-1 using GM-CSF in DNA prime/peptide boost strategy: GM-CSF induced long-lived memory responses. Immunol Lett, 2011; 140, 14−20. doi:  10.1016/j.imlet.2011.05.005
[9] Selvaraj G, Kaliamurthi S, Peslherbe GH, et al. Are the allergic reactions of COVID-19 vaccines caused by mRNA constructs or nanocarriers? Immunological insights. Interdiscip Sci Comput Life Sci, 2021; 13, 344−7. doi:  10.1007/s12539-021-00438-3
[10] Humayun F, Cai YT, Khan A, et al. Structure-guided design of multi-epitopes vaccine against variants of concern (VOCs) of SARS-CoV-2 and validation through In silico cloning and immune simulations. Comput Biol Med, 2022; 140, 105122. doi:  10.1016/j.compbiomed.2021.105122
[11] Harrison T. Viral hepatitis and primary liver cancer. BIOS Scientific Publishers Ltd. 1998.
[12] Wang S, Liu X, Caulfield MJ. Adjuvant synergy in the response to hepatitis B vaccines. Vaccine, 2003; 21, 4297−306. doi:  10.1016/S0264-410X(03)00463-8
[13] Azami M, Ahmadi MRH, Sayehmiri K. Hepatitis B vaccination efficacy in Iranian healthcare workers: a meta-analysis study. Hepat Mon, 2017; 17, e37781.
[14] Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol, 2004; 82, 488−96. doi:  10.1111/j.0818-9641.2004.01272.x
[15] Newton DE. Vaccination Controversies: A Reference Handbook. ABC-CLIO. 2013.
[16] Jamali A, Mahdavi M, Shahabi S, et al. Naloxone, an opioid receptor antagonist, enhances induction of protective immunity against HSV-1 infection in BALB/c mice. Microb Pathog, 2007; 43, 217−23. doi:  10.1016/j.micpath.2007.06.001
[17] Jamali A, Mahdavi M, Hassan ZM, et al. A novel adjuvant, the general opioid antagonist naloxone, elicits a robust cellular immune response for a DNA vaccine. Int Immunol, 2009; 21, 217−25. doi:  10.1093/intimm/dxn139
[18] Yasaghi M, Mahdavi M. Potentiation of human papilloma vaccine candidate using naloxone/alum mixture as an adjuvant: increasing immunogenicity of HPV-16E7d vaccine. Iran J Basic Med Sci, 2016; 19, 1003−9.
[19] Fathi M, Nezamzadeh R, Mahdavi M. Studying the effects of Naloxone-Alum adjuvant mixture on cytokines in model of multi-epitope vaccine in HIV-1. J Chem Health Risks, 2014; 4, 7−14.
[20] Jazani NH, Parsania S, Sohrabpour M, et al. Naloxone and alum synergistically augment adjuvant activities of each other in a mouse vaccine model of Salmonella typhimurium infection. Immunobiology, 2011; 216, 744−51. doi:  10.1016/j.imbio.2010.10.005
[21] Jazani NH, Sohrabpour M, Mazloomi E, et al. A novel adjuvant, a mixture of alum and the general opioid antagonist naloxone, elicits both humoral and cellular immune responses for heat-killed Salmonella typhimurium vaccine. FEMS Immunol Med Microbiol, 2011; 61, 54−62. doi:  10.1111/j.1574-695X.2010.00747.x
[22] Farahani SV, Aghasadeghi MR, Memarnejadian A, et al. Naloxone/alum mixture a potent adjuvant for HIV-1 vaccine: induction of cellular and poly-isotypic humoral immune responses. Pathog Global Health, 2016; 110, 39−47. doi:  10.1179/2047773215Y.0000000035
[23] Savoji MA, Sereshgi MMA, Ghahari SMM, et al. Formulation of HBsAg in Montanide ISA 51VG adjuvant: Immunogenicity study and monitoring long-lived humoral immune responses. Int Immunopharmacol, 2021; 96, 107599. doi:  10.1016/j.intimp.2021.107599
[24] Fathi M, Nezamzadeh R, Abdollahpour-Alitappeh M, et al. Formulation of a recombinant HIV-1 polytope candidate vaccine with naloxone/alum mixture: induction of multi-cytokine responses with a higher regulatory mechanism. APMIS, 2021; 129, 480−8. doi:  10.1111/apm.13122
[25] Pulendran B, Arunachalam PS, O’Hagan DT. Emerging concepts in the science of vaccine adjuvants. Nat Rev Drug Discov, 2021; 20, 454−75. doi:  10.1038/s41573-021-00163-y
[26] Wang H, Huang W, Gao H, et al. NY-ESO-1 protein vaccine combining alum, CpG ODN, and HH2 complex adjuvant induces protective and therapeutic anti-tumor responses in murine multiple myeloma. OncoTargets Ther, 2020; 13, 8069−77. doi:  10.2147/OTT.S255713
[27] Tifrea DF, He W, Pal S, et al. Induction of protection in mice against a Chlamydia muridarum respiratory challenge by a vaccine formulated with the major outer membrane protein in nanolipoprotein particles. Vaccines, 2021; 9, 755. doi:  10.3390/vaccines9070755
[28] Nejati S, Mirzaee S, Nouri HR, et al. Immune responses of mice immunized with HBsAg formulated in naloxone/alum mixture: comparison to fendrix vaccine. Hepat Mon, 2017; 17, e44536.
[29] Shahabi S, Hajipirloo HM, Keramati A, et al. Evaluation of the adjuvant activity of propranolol, a Beta-adrenergic receptor antagonist, on efficacy of a malaria vaccine model in BALB/c mice. Iran J Allergy Asthma Immunol, 2014; 13, 307−16.
[30] Khorshidvand Z, Shahabi S, Mohamadzade H, et al. Mixture of Alum-Naloxone and Alum-Naltrexone as a novel adjuvant elicits immune responses for Toxoplasma gondii lysate antigen in BALB/c mice. Exp Parasitol, 2016; 162, 28−34. doi:  10.1016/j.exppara.2016.01.001
[31] Maynard CL, Elson CO, Hatton RD, et al. Reciprocal interactions of the intestinal microbiota and immune system. Nature, 2012; 489, 231−41. doi:  10.1038/nature11551
[32] Guy B, Krell T, Sanchez V, et al. Do Th1 or Th2 sequence motifs exist in proteins?: Identification of amphipatic immunomodulatory domains in Helicobacter pylori catalase. Immunol Lett, 2005; 96, 261−75. doi:  10.1016/j.imlet.2004.09.011
[33] Bielekova B, Martin R. Antigen-specific immunomodulation via altered peptide ligands. J Mol Med, 2001; 79, 552−65. doi:  10.1007/s001090100259
[34] Motaharinia Y, Rezaee MA, Rashidi A, et al. Induction of protective immunity against brucellosis in mice by vaccination with a combination of naloxone, alum, and heat-killed Brucella melitensis 16 M. J Microbiol Immunol Infect, 2013; 46, 253−8. doi:  10.1016/j.jmii.2012.03.011
[35] Ghadimipour R, Ghorbanpoor M, Gharibi D, et al. Effects of selected adjuvants on immunogenicity and protectivity of Pasteurella multocida bacterin vaccine in chickens. Arch Razi Inst, 2020; 76, 741−9.
[36] Suan D, Nguyen A, Moran I, et al. T follicular helper cells have distinct modes of migration and molecular signatures in naive and memory immune responses. Immunity, 2015; 42, 704−18. doi:  10.1016/j.immuni.2015.03.002